{"id":"insulin-glargine-exenatide","safety":{"commonSideEffects":[{"rate":"20–40","effect":"Nausea"},{"rate":"5–15","effect":"Vomiting"},{"rate":"variable, depends on insulin dose","effect":"Hypoglycemia"},{"rate":"5–10","effect":"Injection site reactions"},{"rate":"10–20","effect":"Diarrhea"},{"rate":"5–10","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Insulin glargine is a long-acting basal insulin that provides steady glucose control by mimicking the pancreas's background insulin secretion. Exenatide is a GLP-1 receptor agonist that enhances insulin release in response to meals, suppresses glucagon, and delays gastric emptying to reduce postprandial glucose spikes. Together, they address both fasting and postprandial hyperglycemia in type 2 diabetes.","oneSentence":"This combination drug lowers blood glucose by providing basal insulin coverage while simultaneously stimulating insulin secretion and slowing gastric emptying through GLP-1 receptor activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:34.012Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus (in development)"}]},"trialDetails":[{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT01107717","phase":"PHASE4","title":"Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-01","conditions":"Diabetes","enrollment":318},{"nctId":"NCT01524705","phase":"PHASE4","title":"FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-08","conditions":"Type 2 Diabetes","enrollment":102},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT02194595","phase":"PHASE3","title":"Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2014-09","conditions":"Type 2 Diabetes","enrollment":105},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT01269034","phase":"PHASE4","title":"New Onset Type 1 Diabetes: Role of Exenatide","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2010-12","conditions":"Type 1 Diabetes","enrollment":13},{"nctId":"NCT04027023","phase":"PHASE4","title":"Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Sciema UG","startDate":"2019-10-30","conditions":"Diabetes Mellitus, Type 2","enrollment":9},{"nctId":"NCT02690883","phase":"PHASE4","title":"Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-04-08","conditions":"Diabetic Nephropathies","enrollment":92},{"nctId":"NCT02072096","phase":"PHASE4","title":"A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":192},{"nctId":"NCT02303730","phase":"PHASE4","title":"Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes","status":"COMPLETED","sponsor":"Fudan University","startDate":"2015-03","conditions":"Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease","enrollment":76},{"nctId":"NCT02455076","phase":"PHASE4","title":"Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-09","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT03959865","phase":"","title":"GLP-1 REceptor Agonists and Real World EvIdeNce","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2018-12-19","conditions":"Type 2 Diabetes","enrollment":6000},{"nctId":"NCT02229383","phase":"PHASE3","title":"Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-06","conditions":"Diabetes Mellitus","enrollment":464},{"nctId":"NCT02467920","phase":"PHASE4","title":"Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM","status":"COMPLETED","sponsor":"Huazhong University of Science and Technology","startDate":"2015-08","conditions":"Type 2 Diabetes Mellitus","enrollment":349},{"nctId":"NCT01269047","phase":"PHASE4","title":"Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2009-08","conditions":"Type 1 Diabetes","enrollment":37},{"nctId":"NCT00353834","phase":"PHASE4","title":"The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes","status":"COMPLETED","sponsor":"Joslin Diabetes Center","startDate":"2006-08","conditions":"Type 2 Diabetes Mellitus","enrollment":72},{"nctId":"NCT02843399","phase":"","title":"Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-08-15","conditions":"Diabetes Mellitus Type 2","enrollment":15498},{"nctId":"NCT01089569","phase":"NA","title":"Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2010-04","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT02811484","phase":"PHASE4","title":"Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2016-06","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT00855439","phase":"NA","title":"Evaluation of Exenatide in Patients With Diabetic Neuropathy","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2008-06","conditions":"Type 2 Diabetes Mellitus, Diabetic Peripheral Neuropathy","enrollment":46},{"nctId":"NCT02325960","phase":"PHASE4","title":"A Comparison of Exenatide and Insulin Glargine","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2015-01","conditions":"Type 2 Diabetes","enrollment":44},{"nctId":"NCT00765817","phase":"PHASE3","title":"Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-10","conditions":"Type 2 Diabetes","enrollment":261},{"nctId":"NCT02887625","phase":"NA","title":"Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM","status":"UNKNOWN","sponsor":"Dr. Muhammad Abdulghani","startDate":"2015-02","conditions":"Type 2 Diabetes","enrollment":410},{"nctId":"NCT00766857","phase":"PHASE4","title":"Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2009-05","conditions":"Type 2 Diabetes Mellitus, Congestive Heart Failure","enrollment":27},{"nctId":"NCT01237314","phase":"","title":"The Impact of Food on Blood Sugar in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2010-11","conditions":"Type 2 Diabetes","enrollment":46},{"nctId":"NCT00935532","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-07","conditions":"Type 2 Diabetes Mellitus","enrollment":427},{"nctId":"NCT00641056","phase":"PHASE3","title":"Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Type 2 Diabetes Mellitus","enrollment":467},{"nctId":"NCT00082381","phase":"PHASE3","title":"Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-06","conditions":"Diabetes Mellitus, Type 2","enrollment":551},{"nctId":"NCT00960661","phase":"PHASE3","title":"A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":1036},{"nctId":"NCT00360334","phase":"PHASE3","title":"A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-06","conditions":"Type 2 Diabetes","enrollment":235},{"nctId":"NCT00097500","phase":"PHASE3","title":"Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Type 2 Diabetes Mellitus","enrollment":69},{"nctId":"NCT00099619","phase":"PHASE3","title":"Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Type 2 Diabetes Mellitus","enrollment":138},{"nctId":"NCT00667732","phase":"PHASE4","title":"How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2007-03","conditions":"Type 2 Diabetes","enrollment":41},{"nctId":"NCT00560417","phase":"PHASE3","title":"Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-11","conditions":"Diabetes Mellitus, Type 2","enrollment":339},{"nctId":"NCT00971659","phase":"PHASE1","title":"Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes","status":"COMPLETED","sponsor":"Profil Institut für Stoffwechselforschung GmbH","startDate":"2008-01","conditions":"Type 2 Diabetes","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Byetta","AC2993","synthetic exenden-4"],"phase":"phase_3","status":"active","brandName":"insulin glargine/exenatide","genericName":"insulin glargine/exenatide","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug lowers blood glucose by providing basal insulin coverage while simultaneously stimulating insulin secretion and slowing gastric emptying through GLP-1 receptor activation. Used for Type 2 diabetes mellitus (in development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}